title: Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study.
abstract: OBJECTIVE
  We aimed to evaluate the long-term safety and efficacy of the STENTYS self-apposing paclitaxeleluting stent (STENTYS-PES) in bifurcation lesions in routine clinical practice.
  
  
  RESULTS
  The primary endpoint of the study was the composite major adverse cardiac events (MACE: cardiac death, myocardial infarction, clinically driven target lesion revascularisation, or emergent bypass surgery) assessed at six months after enrolment. This was reported in 21 patients (10.1%), mainly due to clinically driven target lesion revascularisation (TLR). At 12 months, 27 patients experienced MACE (13.0%).
  
  
  CONCLUSIONS
  The long-term results of OPEN II show that the STENTYS-PES is safe and effective in the treatment of all-comers with coronary bifurcation lesions.
authors.affiliation: Contilia Heart and Vascular Center, Elisabeth-Krankenhaus, Essen, Germany.
authors.forename: Christoph K
authors.initials: CK
authors.lastname: Naber
authors.forename: Stylianos A
authors.initials: SA
authors.lastname: Pyxaras
authors.forename: Holger
authors.initials: H
authors.lastname: Nef
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: IJsselmuiden
authors.forename: Carlo
authors.initials: C
authors.lastname: Briguori
authors.forename: Christian
authors.initials: C
authors.lastname: Schlundt
authors.forename: Joanna
authors.initials: J
authors.lastname: Wykrzykowska
authors.forename: Franz R
authors.initials: FR
authors.lastname: Eberli
authors.forename: Helge
authors.initials: H
authors.lastname: Möllmann
authors.forename: Søren
authors.initials: S
authors.lastname: Galatius
authors.forename: Johannes
authors.initials: J
authors.lastname: Rieber
authors.forename: Philippe
authors.initials: P
authors.lastname: Commeau
authors.forename: Robert-Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: David
authors.initials: D
authors.lastname: Bouchez
authors.forename: Harald
authors.initials: H
authors.lastname: Mudra
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology; D003328:Coronary Thrombosis / Q000628:therapy; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use; D013995:Time; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus